Medpace (NASDAQ:MEDP) is a top pick for this investor
Medpace Holdings (Medpace Holdings Stock Quote, Chart, News, Analysts, Financials NASDAQ:MEDP) offers investors exposure to the biotechnology industry’s recovery without taking on the risks associated with developing individual drugs, according to Julien Nono-Womdim, vice president at Goodreid Investment Counsel.
Speaking on BNN Bloomberg’s Market Call on Nov. 18, Nono-Womdim named Medpace as one of his top picks, citing the pharmaceutical industry’s growing reliance on outsourced clinical research and improving biotechnology investment.
“When investing in biotech, you can either go directly to the biotech companies or you can sort of invest around the ecosystem,” he said.
Medpace is a contract research organization (CRO) that helps pharmaceutical and biotechnology companies conduct clinical trials, from early Phase 1 studies through Phase 4 post-approval research. Its services include recruiting trial participants, managing clinical studies and preparing documentation required by regulators to evaluate drug safety and effectiveness.
Nono-Womdim said pharmaceutical companies have increasingly outsourced these activities over the past 15 to 20 years, creating opportunities for specialized research providers.
Medpace focuses primarily on smaller and emerging biotechnology companies, which often lack the resources to manage clinical trials internally.
“Medpace is a very interesting company because they skew towards smaller and emerging biotechnology companies, so the companies that don’t necessarily have the resources to do the clinical trials in-house, and so they outsource pretty much everything to a company like Medpace,” he said.
The investor believes the company could benefit from two trends: continued outsourcing of clinical research and a recovery in spending by biotechnology companies.
Venture capital investment and other financing activity suggest that funding conditions in the sector are improving, potentially supporting additional clinical trials and demand for Medpace’s services.
“Structurally, we think that outsourcing is going to be here to stay,” Nono-Womdim said. “We think that cyclically, biopharma spending has recovered. If you look at VC spending, etc., the indications are positive.”
Although he acknowledged that Medpace trades at a relatively high valuation, he believes its business model and growth opportunities justify the premium. “Valuation’s a bit high, but the premium valuation is justified,” he said.
-30-
Rod Weatherbie
Writer
Rod Weatherbie is a journalist based in Prince Edward Island. Since 2004, he has written extensively about the Canadian property and casualty insurance landscape. He was also a founder and contributing editor for a Toronto-based arts website and a PEI-based food magazine. His fiction and poetry have been featured in The Fiddlehead, The Antigonish Review, and Juniper.